

Catalytic, Enantioselective Synthesis of Stilbene *cis*-Diamines:
A Concise Preparation of (-)-Nutlin 3, a Potent p53-MDM2 Inhibitor


Tyler A. Davis and Jeffrey N. Johnston*

Department of Chemistry & Vanderbilt Institute of Chemical Biology
Vanderbilt University
2301 Vanderbilt Place, Nashville, TN 37235-1822

S-I-X

Hoffmann-La Roche Patent Synthesis.....	2
Experimental Section.....	2
<i>tert</i> -Butyl (1 <i>R</i> ,2 <i>S</i>)-1-(3-bromo-4-methoxyphenyl)-2-nitro-2-phenylethylcarbamate (S1).....	3
Isopropyl 2-isopropoxy-4-methoxybenzoate (S2).....	3
<i>tert</i> -Butyl (1 <i>R</i> ,2 <i>S</i>)-2-amino-1,2-bis(4-chlorophenyl)ethylcarbamate (S3).....	3
<i>N</i> -((1 <i>S</i> ,2 <i>R</i>)-2-Amino-1,2-bis(4-chlorophenyl)ethyl)-2-isopropoxy-4-methoxybenzamide (S4).....	4
2,4-Dichloro-6-methoxyquinoline (S5).....	4
H, ⁴ Cl ⁶ MeOQuin-BAM (S6).....	5
2,4-Dichloro-7-methoxyquinoline (S7).....	5
H, ⁴ Cl ⁷ MeOQuin-BAM (S8).....	6
H, ⁴ Cl ^{6,7} (MeO) ₂ Quin-BAM (S9).....	6
<i>N</i> -((1 <i>R</i> ,2 <i>S</i>)-1,2-Bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxybenzamido)ethyl)-3-oxopiperazine-1-carboxamide (S10).....	6
<i>tert</i> -Butyl (1 <i>R</i> ,2 <i>S</i>)-1,2-bis(4-chlorophenyl)-2-nitroethylcarbamate (1a).....	7
<i>tert</i> -Butyl (1 <i>R</i> ,2 <i>S</i>)-1-(4-chlorophenyl)-2-nitro-2-phenylethylcarbamate (1b).....	7
<i>tert</i> -Butyl (1 <i>R</i> ,2 <i>S</i>)-1-(4-(allyloxy)phenyl)-2-nitro-2-phenylethylcarbamate (1c).....	8
<i>tert</i> -Butyl (1 <i>R</i> ,2 <i>S</i>)-1-(4-methoxyphenyl)-2-nitro-2-phenylethylcarbamate (1d).....	8
<i>tert</i> -Butyl (1 <i>R</i> ,2 <i>S</i>)-2-nitro-2-phenyl-1-p-tolylethylcarbamate (1e).....	8
<i>tert</i> -Butyl (1 <i>R</i> ,2 <i>S</i>)-1-(4-fluorophenyl)-2-nitro-2-phenylethylcarbamate (1f).....	9
<i>tert</i> -Butyl (1 <i>R</i> ,2 <i>S</i>)-2-nitro-2-phenyl-1-(4-(trifluoromethyl)phenyl)ethylcarbamate (1g).....	9
<i>tert</i> -Butyl (1 <i>R</i> ,2 <i>S</i>)-1-(biphenyl-4-yl)-2-nitro-2-phenylethylcarbamate (1h).....	9
<i>tert</i> -Butyl (1 <i>R</i> ,2 <i>S</i>)-1-(naphthalen-2-yl)-2-nitro-2-phenylethylcarbamate (1i).....	10
<i>tert</i> -Butyl (1 <i>R</i> ,2 <i>S</i>)-2-(3-bromophenyl)-1-(4-chlorophenyl)-2-nitroethylcarbamate (1j).....	10
<i>tert</i> -Butyl (1 <i>R</i> ,2 <i>S</i>)-1-(4-chlorophenyl)-2-(naphthalen-2-yl)-2-nitroethylcarbamate (1k).....	10
<i>tert</i> -Butyl (1 <i>R</i> ,2 <i>S</i>)-1-(4-chlorophenyl)-2-(4-methoxyphenyl)-2-nitroethylcarbamate (1l).....	11
<i>tert</i> -Butyl (1 <i>R</i> ,2 <i>S</i>)-1-(4-chlorophenyl)-2-nitro-2-(4-nitrophenyl)ethylcarbamate (1m).....	11
(-)-Nutlin-3 (2).....	11
1-Chloro-4-(nitromethyl)benzene (4).....	12
H, ⁶ Me-BAM (7).....	13
H, ⁴ PyrrolidineQuin-BAM·HOTf (8a·HOTf).....	13
H, ⁴ Pyrrolidine ⁶ MeOQuin-BAM (8b).....	13
H, ⁴ Pyrrolidine ⁷ MeOQuin-BAM (8c).....	14
H, ⁴ Pyrrolidine ^{6,7} (MeO) ₂ Quin-BAM (8d).....	14
1-Bromo-3-(nitromethyl)benzene (17).....	15
2-(Nitromethyl)naphthalene (18).....	15
2-Isopropoxy-4-methoxybenzoic acid (21).....	15
<i>tert</i> -Butyl (1 <i>R</i> ,2 <i>S</i>)-1,2-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxybenzamido)ethylcarbamate (22).....	16
2-Oxo-piperazine (23).....	16

Hoffmann-La Roche Patent Synthesis



Vogtle, F.; Goldschmitt, E. *Chem. Ber.* **1976**, *109*, 1-40

Experimental Section


All reagents and solvents were commercial grade and purified prior to use when necessary. The following reagents were used as supplied by Sigma-Aldrich without further purification except when noted otherwise. Aldimines were prepared as reported in the literature.¹ 2,4-Dichloro-6,7-dimethoxyquinoline was prepared with a procedure similar to that of **S5** and **S7**. Toluene was dried by passage through a column of activated alumina as described by Grubbs.² Thin layer chromatography (TLC) was performed using glass-backed silica gel (250 µm) plates and flash chromatography utilized 230–400 mesh silica gel from Sorbent Technologies. UV light, and/or the use of potassium iodoplatinate and potassium permanganate solutions were used to visualize products. IRA-900-NO₂ resin was prepared by washing IRA900-Cl resin with aq NaNO₂ until the wash no longer tested positive for chloride by a AgNO₃ test.

Nuclear magnetic resonance spectra (NMR) were acquired on a Bruker DRX-500 (500 MHz), Bruker AV-400 (400 MHz) or Bruker AV II-600 (600 MHz) instrument. Chemical shifts are measured relative to residual solvent peaks as an internal standard set to δ 7.26 and δ 77.0 (CDCl₃). IR spectra were recorded on a Thermo Nicolet IR100 spectrophotometer and are reported in wavenumbers (cm⁻¹). Compounds were analyzed as neat films on a NaCl plate (transmission). Mass spectra were recorded on a Waters LCT spectrometer by use of the ionization method noted.


Absolute and relative configuration of **1a** was assigned by analogy to **S1**, for which a crystal structure was obtained (*see SI-2*).

¹ Kanazawa, A. M.; Denis, J.; Greene, A. E. *J. Org. Chem.* **1994**, *59*, 1238-1240.


² Pangborn, A. B.; Giardello, M. A.; Grubbs, R. H.; Rosen, R. K.; Timmers, F. J. *Organometallics* **1996**, *15*, 1518-1520.



tert-Butyl (1*R*,2*S*)-1-(3-bromo-4-methoxyphenyl)-2-nitro-2-phenylethylcarbamate (S1). *tert*-Butyl 3-bromo-4-methoxybenzylidene carbamate (62.8 mg, 200 μ mol) and H_4^4 PyrrolidineQuin-BAM (5.1 mg, 10 μ mol) were dissolved in toluene (2 mL) at room temperature. The solution was chilled to -78 °C before addition of nitromethylbenzene (41.1 mg, 300 μ mol). The reaction was then stirred at -78 °C for 20 h. The reaction was kept at the reaction temperature until filtering through a pad of silica with CH_2Cl_2 and EtOAc. The filtrate was concentrated and then purified by column chromatography (5-40% ethyl acetate in hexanes) to afford a white solid (67.1 mg, 74%) that was found to be 73% ee by chiral HPLC; (Chiralcel IA, 5% iPrOH/hexanes, 1 mL/min, t_r (*anti*, major) = 61.8 min, t_r (*anti*, minor) = 29.2 min, t_r (*syn*, major) = 26.8 min, t_r (*syn*, minor) = 49.6 min); Mp 157.0-159.0 °C; R_f = 0.19 (20% EtOAc/hexanes); IR (film) 3387, 2979, 1685, 1553 cm^{-1} ; 1H NMR (400 MHz, $CDCl_3$) δ 7.55 (dd, J = 7.2, 2.0 Hz, 2H), 7.53 (d, J = 2.0 Hz, 1H), 7.46-7.38 (m, 3H), 7.30-7.25 (dd, J = 8.4, 2.0 Hz, 1H), 6.86 (d, J = 8.4 Hz, 1H), 5.72 (d, J = 10.0 Hz, 1H), 5.58 (dd, J = 9.2, 9.2 Hz, 1H), 4.77 (d, J = 8.8 Hz, 1H), 3.89 (s, 3H), 1.26 (s, 9H); ^{13}C NMR (150 MHz, $CDCl_3$) ppm 156.1, 154.1, 131.9, 131.3, 131.1, 130.3, 128.9 (2C), 128.7 (2C), 127.7, 112.1, 112.0, 94.1, 80.5, 56.2, 55.8, 28.0; HRMS (ESI): Exact mass calcd for $C_{20}H_{23}BrN_2NaO_5$ [M+Na]⁺ 473.0688, found 473.0711.




Isopropyl 2-isopropoxy-4-methoxybenzoate (S2).³ Isopropyl bromide (2.926 g, 23.79 mmol) was added to a stirred mixture of 4-methoxysalicylic acid (1.000 g, 5.947 mmol), K_2CO_3 (3.286 g, 23.79 mmol), and dry DMF (30 mL) at room temperature. The mixture was allowed to stir for 20 min before heating to reflux for 31 h. The reaction mixture was cooled to room temperature, treated with KI (98.7 mg, 595 μ mol) and stirred for 17 h. The reaction was quenched with 1 M aq HCl then extracted with diethyl ether. The combined organic layers were washed with 1 M aq Na_2CO_3 , water, then brine before drying over $MgSO_4$. Concentration of the dried organic layers resulted in a bronze oil (1.0549 g, 70%) that was pure by 1H NMR. R_f = 0.16 (5% EtOAc/hexanes); IR (film) 2979, 2936, 1721, 1694, 1608, 1575 cm^{-1} ; 1H NMR (400 MHz, $CDCl_3$) δ 7.77 (d, J = 7.2 Hz, 1H), 6.49-6.43 (m, 2H), 5.20 (heptet, J = 6.4 Hz, 1H), 4.55 (heptet, J = 6.0 Hz, 1H), 3.81 (s, 3H), 1.36 (d, J = 6.0 Hz, 6H), 1.33 (d, J = 6.0 Hz, 6H); ^{13}C NMR (100 MHz, $CDCl_3$) ppm 165.8, 163.5, 159.3, 133.4, 114.9, 104.9, 101.8, 71.5, 67.5, 55.4, 22.0 (2C); HRMS (CI): Exact mass calcd for $C_{14}H_{21}O_4$ [M+H]⁺ 253.1434, found 253.1431.




tert-Butyl (1*R*,2*S*)-2-amino-1,2-bis(4-chlorophenyl)ethylcarbamate (S3). The nitroalkane (411.3 mg, 1.000 mmol) was dissolved in MeOH (4.0 mL) at room temperature. $CoCl_2$ (129.8 mg, 1.000 mmol) was added and the reaction mixture was chilled to 0 °C before $NaBH_4$ (567.6 mg, 15.00 mmol) was added in three portions over 40 min. The reaction mixture was stirred at 0 °C for an additional 30 min before the mixture was quenched with sat. aq. NH_4Cl . The reaction mixture was adjusted to pH 10 with conc. aq. NH_4OH . The mixture was extracted with ethyl acetate, dried over $MgSO_4$, and concentrated. Column chromatography (25-45% ethyl acetate in hexanes) of the residue afforded the product as a white solid (251.7 mg, 66%). Mp 149.0-150.0 °C;

³ Adapted from: Hattori, T.; Shimazumi, Y.; Goto, H.; Yamabe, O.; Morohashi, N.; Kawai, W.; Miyano, S. *J. Org. Chem.* **2003**, 68, 2099-2108.


$[\alpha]_D^{20} +67$ (*c* 0.12, CHCl₃); R_f = 0.12 (50% EtOAc/hexanes); IR (film) 3377, 2981, 1683, 1523 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.24 (d, *J* = 8.4 Hz, 2H), 7.21 (d, *J* = 8.4 Hz, 2H), 7.00 (d, *J* = 8.4 Hz, 2H), 6.93 (d, *J* = 8.4 Hz, 2H), 5.49 (d, *J* = 7.6 Hz, 1H), 4.79 (br s, 1H), 4.23 (br s, 1H), 1.50 (s, 2H), 1.36 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) ppm 155.0, 140.3 (2C), 133.3, 133.2, 128.7, 128.4, 128.2 (2C), 79.8, 59.5, 59.1, 28.2; HRMS (ESI): Exact mass calcd for C₁₉H₂₃Cl₂N₂O₂ [M+H]⁺ 381.1137, found 381.1147.




N-((1*S*,2*R*)-2-Amino-1,2-bis(4-chlorophenyl)ethyl)-2-isopropoxy-4-methoxybenzamide (S4). Amide (180.0 mg, 313.9 μmol) was dissolved in CH₂Cl₂ (3.1 mL). TFA (932 μL, 12.6 mmol) was added and the mixture was stirred at room temperature for 16 h. The reaction mixture was poured into satd. aq. NaHCO₃ and extracted with CH₂Cl₂. The combined organic layers were dried over MgSO₄, filtered, and concentrated to a light brown foam (130.3 mg, 88%). $[\alpha]_D^{20} -140$ (*c* 0.11, CHCl₃); R_f = 0.46 (10% MeOH/CH₂Cl₂); IR (film) 3376, 2925, 2853, 1644, 1605, 1521 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 8.88 (d, *J* = 8.0 Hz, 1H), 8.13 (d, *J* = 8.8 Hz, 1H), 7.24 (d, *J* = 8.4 Hz, 2H), 7.20 (d, *J* = 8.4 Hz, 2H), 7.03 (d, *J* = 8.4 Hz, 2H), 7.00 (d, *J* = 8.8 Hz, 2H), 6.56 (dd, *J* = 8.8, 2.4 Hz, 1H), 6.49 (d, *J* = 2.0 Hz, 1H), 5.43 (dd, *J* = 8.0, 4.8 Hz, 1H), 4.75 (qq, *J* = 6.0, 6.0 Hz, 1H), 4.41 (d, *J* = 4.8 Hz, 1H), 3.83 (s, 3H), 1.45 (d, *J* = 5.6 Hz, 3H), 1.44 (d, *J* = 5.6 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) ppm 164.7, 163.3, 157.2, 140.7, 136.8, 134.1, 133.2, 133.1, 129.1, 128.4, 128.3, 128.2, 115.0, 105.1, 100.3, 71.5, 59.0, 58.6, 55.5, 22.2, 22.0; HRMS (ESI): Exact mass calcd for C₂₅H₂₇Cl₂N₂O₃ [M+H]⁺ 473.1399, found 473.1400.



2,4-Dichloro-6-methoxyquinoline (S5). Phosphorus(V) oxychloride (40 mL, 1.5 M) was added through a condenser into a 3-neck round bottom flask containing malonic acid (6.244 g, 60.00 mmol) and a stir bar at room temperature. While stirring, *p*-anisidine (9.236 g, 75.00 mmol) was added in small portions over a period of 15 minutes through an open neck of the round bottom flask. The reaction mixture was heated and stirred at reflux for 5 hours. The reaction mixture was allowed to cool to room temperature before it was poured over crushed ice (~700 mL). The pH of the resulting aqueous solution was then adjusted to 10 with concentrated ammonium hydroxide (~85 mL). The aqueous suspension was extracted with dichloromethane. The combined organic layers were then dried over MgSO₄ before concentration. Purification by column chromatography (0–5% ethyl acetate in hexanes) yielded the title compound as a slightly yellow solid (4.7812 g, 35%). Mp 170.5–171.5 °C; R_f = 0.27 (2% EtOAc/hexanes); IR (film) 3084, 3013, 2982, 1623, 1562, 1499 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 7.90 (d, *J* = 9.0 Hz, 1H), 7.45 (s, 1H), 7.40 (dd, *J* = 9.0, 3.0 Hz, 1H), 7.36 (d, *J* = 3.0 Hz, 1H), 3.96 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) ppm 158.9, 147.0, 144.0, 142.6, 130.4, 126.3, 124.1, 122.0, 101.9, 55.7; HRMS (CI): Exact mass calcd for C₁₀H₈Cl₂NO [M+H]⁺ 227.9977, found 227.9974.




H,⁴Cl⁶MeOQuin-BAM (S6). A 2-5 mL μW vial was charged with (*R,R*)-diaminocyclohexane (125.2 mg, 1.096 mmol), 2,4-dichloro-6-methoxyquinoline (500 mg, 2.190 mmol), $\text{Pd}(\text{dba})_2$ (12.6 mg, 22.0 μmol), *rac*-BINAP (13.6 mg, 22.0 μmol), and sodium *tert*-butoxide (316.2 mg, 3.290 mmol).⁴ Trifluoromethylbenzene (3.8 mL) was added and the resulting suspension was heated at 120°C and stirred in the microwave for 10 min. The reaction mixture was triturated with CH_2Cl_2 and filtered. The filtrate was concentrated and purified by column chromatography (10-20% ethyl acetate in hexanes) to provide a yellow solid (420.3 mg, 77%) that was pure by ¹H NMR; $[\alpha]_D^{20} +610$ (*c* 0.18, CHCl_3); $R_f = 0.18$ (20% EtOAc/hexanes); IR (film) 3218, 2925, 1605, 1495 cm^{-1} ; ¹H NMR (600 MHz, CDCl_3 , 325 K) δ 7.64 (d, *J* = 9.0 Hz, 2H), 7.30 (d, *J* = 3.0 Hz, 2H), 7.25 (dd, *J* = 9.0, 3.0 Hz, 2H), 6.38 (br s, 2H), 5.72 (br s, 2H), 4.05-3.90 (m, 2H), 3.91 (s, 6H), 2.39-2.25 (m, 2H), 1.90-1.80 (m, 2H), 1.55-1.35 (m, 4H); ¹³C NMR (150 MHz, CDCl_3 , 325 K) ppm 155.5, 155.4, 144.0, 141.4, 127.6, 121.9, 121.8, 111.8, 103.7, 56.1, 55.6, 33.0, 24.9; HRMS (ESI): Exact mass calcd for $\text{C}_{26}\text{H}_{27}\text{Cl}_2\text{N}_4\text{O}_2$ [$\text{M}+\text{H}]^+$ 497.1511, found 497.1500.




2,4-Dichloro-7-methoxyquinoline (S7). Phosphorus(V) oxychloride (20 mL, 1.3 M) was added through a running condenser into a 3-neck round bottom flask equipped with a stir bar containing malonic acid (2.710 g, 26.00 mmol) at room temperature. While stirring, *m*-anisidine (4.000 g, 32.48 mmol) was added in small portions over a period of 15 minutes through an open neck of the round bottom flask. The reaction mixture was heated and stirred at reflux for 5 hours. The reaction mixture was allowed to cool to room temperature before it was poured over crushed ice (~350 mL). The pH of the resulting aqueous solution was adjusted to 10 with concentrated ammonium hydroxide. The aqueous suspension was extracted with dichloromethane. The combined organic layers were dried over MgSO_4 and filtered before concentration to provide a 2.2:1 mixture (¹H NMR) of the 7-methoxy and 5-methoxy regioisomers. Purification by column chromatography (0-8% ethyl acetate in hexanes) yielded a white solid (3.181 g, 54%) that was recrystallized from ethyl acetate and hexanes to provide the 7-methoxy isomer. Mp 131.5-132.5 °C; $R_f = 0.18$ (5% EtOAc/hexanes); IR (film) 3092, 2982, 1623, 1572, 1559 cm^{-1} ; ¹H NMR (400 MHz, CDCl_3) δ 8.01 (d, *J* = 9.2 Hz, 1H), 7.32 (s, 1H), 7.31 (d, *J* = 2.4 Hz, 1H), 7.23 (dd, *J* = 9.2, 2.4 Hz, 1H), 3.92 (s, 3H); ¹³C NMR (100 MHz, CDCl_3) ppm 162.2, 150.2, 150.0, 143.9, 125.2, 120.7, 120.1, 119.5, 107.1, 55.7; HRMS (ESI): Exact mass calcd for $\text{C}_{10}\text{H}_8\text{Cl}_2\text{NO}$ [$\text{M}+\text{H}]^+$ 227.9977, found 227.9973.


⁴ Adapted from Wagaw, S.; Rennels, R.; Buchwald, S. *J Am. Chem. Soc.* **1997**, *119*, 8451-8458.



H,⁴Cl⁷MeOQuin-BAM (S8). A 2-5 mL μ W vial was charged with (*R,R*)-diaminocyclohexane (125.2 mg, 1.096 mmol), 2,4-dichloro-7-methoxyquinoline (500 mg, 2.190 mmol), Pd(dba)₂ (12.6 mg, 22.0 μ mol), *rac*-BINAP (13.6 mg, 22.0 μ mol), and sodium *tert*-butoxide (316.2 mg, 3.290 mmol).⁴ Trifluoromethylbenzene (3.8 mL) was added and the resulting suspension was heated at 100 °C and stirred in the microwave for 10 min. The reaction mixture was diluted with CH₂Cl₂ and filtered through Celite. The filtrate was concentrated and washed with CH₂Cl₂ then hexanes to provide a light brown powder (412.9 mg, 76%) that was pure by ¹H NMR; $[\alpha]_D^{20}$ +580 (*c* 0.19, CHCl₃); R_f = 0.25 (50% EtOAc/hexanes); IR (film) 3220, 2933, 1610, 1510 cm⁻¹; ¹H NMR (500 MHz, CDCl₃, 325 K) δ 7.82 (d, *J* = 9.0 Hz, 2H), 7.08 (s, 2H), 6.91 (dd, *J* = 9.0, 2.5 Hz, 2H), 6.31 (br s, 2H), 5.64 (br s, 2H), 4.09 (br s, 2H), 3.94 (s, 6H), 2.41-2.32 (m, 2H), 1.90-1.80 (m, 2H), 1.55-1.38 (m, 4H); ¹³C NMR (100 MHz, CDCl₃, 325 K) ppm 162.0, 157.3, 150.5, 142.3, 125.3, 116.3, 114.4, 109.5, 106.0, 56.1, 55.5, 32.9, 24.9; HRMS (ESI): Exact mass calcd for C₂₆H₂₇Cl₂N₄O₂ [M+H]⁺ 497.1511, found 497.1501.



H,⁴Cl^{6,7}(MeO)₂Quin-BAM (S9). A 10-20 mL μ W vial was charged with (*R,R*)-diaminocyclohexane (442.4 mg, 3.874 mmol), 2,4-dichloro-6,7-dimethoxyquinoline (2.000 g, 7.749 mmol), Pd(dba)₂ (44.5 mg, 77.48 μ mol), *rac*-BINAP (48.2 mg, 77.48 μ mol), and sodium *tert*-butoxide (1.117 g, 11.62 mmol).⁴ Trifluoromethylbenzene (13.4 mL) was added and the resulting suspension was heated at 100 °C and stirred in the microwave for 10 min. The reaction mixture was filtered through celite with CH₂Cl₂ and concentrated. The residue was triturated with ethyl acetate and hexanes to provide a light brown powder (1.4612 g, 68%) that was sufficiently pure by ¹H NMR; $[\alpha]_D^{20}$ +410 (*c* 0.10, CHCl₃); R_f = 0.15 (50% EtOAc/hexanes); IR (film) 3223, 2930, 1600 cm⁻¹; ¹H NMR (400 MHz, CDCl₃, 330 K) δ 7.24 (s, 2H), 7.09 (s, 2H), 6.32 (br s, 2H), 5.50 (br s, 2H), 4.02 (s, 6H), 4.00 (br s, 2H), 3.97 (s, 6H), 2.38-2.28 (m, 2H), 1.90-1.80 (m, 2H), 1.55-1.35 (m, 4H); ¹³C NMR (100 MHz, CDCl₃, 330 K) ppm 156.2, 153.2, 147.1, 145.3, 141.0, 115.7, 109.2, 106.6, 103.6, 56.2 (2C), 56.1, 33.0, 24.9; HRMS (CI): Exact mass calcd for C₂₈H₃₁Cl₂N₄O₄ [M+H]⁺ 557.1717, found 557.1717.




N-((1R,2S)-1,2-Bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxybenzamido)ethyl)-3-oxopiperazine-1-carbox-amide (S10). Amine (100.0 mg, 211.2 μ mol) was dissolved in CH₂Cl₂ (1.0 mL) and stirred at room

Johnston et al.


Supporting Information

temperature. CDI (41.1 mg, 253.5 μmol) was added and the reaction was stirred for 1 h. 2-Oxo-piperazine (42.3 mg, 422.4 μmol) was added, and the reaction mixture was stirred for an additional 4 hours. The reaction mixture was concentrated and purified by column chromatography (0-2-5% methanol in dichloromethane) to provide a white solid (119.6 mg, 94%). $[\alpha]_D^{20} +110$ (*c* 0.14, CHCl_3); $R_f = 0.34$ (10% MeOH/ CH_2Cl_2); IR (film) 3369, 2978, 2932, 2243, 1634, 1605 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 8.37 (d, *J* = 8.0 Hz, 1H), 8.28 (d, *J* = 8.8 Hz, 1H), 7.80 (d, *J* = 4.8 Hz, 1H), 7.29 (d, *J* = 8.4 Hz, 2H), 7.17 (d, *J* = 8.4 Hz, 2H), 6.95 (d, *J* = 8.4 Hz, 2H), 6.88 (d, *J* = 8.4 Hz, 2H), 6.62 (dd, *J* = 8.8, 2.0 Hz, 1H), 6.46 (d, *J* = 2.0 Hz, 1H), 6.15 (br s, 1H), 5.77 (dd, *J* = 7.6, 2.0 Hz, 1H), 5.10 (dd, *J* = 8.8, 2.4 Hz, 1H), 4.66 (qq, *J* = 6.0, 6.0 Hz, 1H), 4.15 (d, *J* = 2.4 Hz, 2H), 3.86 (s, 3H), 3.73 (ddd, *J* = 13.2, 5.6, 4.4 Hz, 1H), 3.60 (ddd, *J* = 13.2, 6.4, 4.4 Hz, 1H), 3.46-3.35 (m, 2H), 1.20 (d, *J* = 6.0 Hz, 3H), 1.14 (d, *J* = 6.0 Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) ppm 168.0, 167.0, 163.0, 157.2, 155.9, 136.7, 136.6, 134.3, 133.8, 133.2, 129.4, 128.6, 128.4, 128.0, 113.5, 105.4, 100.3, 71.4, 61.6, 57.5, 55.5, 47.4, 40.9, 39.9, 21.9, 21.5; HRMS (CI): Exact mass calcd for $\text{C}_{30}\text{H}_{33}\text{Cl}_2\text{N}_4\text{O}_5$ [$\text{M}+\text{H}]^+$ 599.1823, found 599.1814.



tert-Butyl (1*R*,2*S*)-1,2-bis(4-chlorophenyl)-2-nitroethylcarbamate (1a). Imine (1.5000 g, 6.2580 mmol) and $\text{H}^4\text{Pyrrolidine}^{6,7}(\text{MeO})_2\text{Quin-BAM}$ (196.1 mg, 312.9 μmol) were dispensed into a 100 mL round bottom flask equipped with stir bar. Toluene (63 mL) was added and the mixture was chilled to -78 °C before addition of the nitroalkane **9** (1.1810 g, 6.8840 mmol). The reaction was stirred at -78 °C for 24 h. The reaction was kept at the reaction temperature and filtered directly through a pad of silica gel with CH_2Cl_2 . The filtrate was concentrated to give 2.2772 g of a white solid that was 6:1 *anti:syn*. A portion (1.1000 g) of this material was recrystallized from toluene to provide colorless crystals. The crystalline material (586.8 mg) was separated from the mother liquor and found to be >200:1 dr, 97% ee by chiral HPLC; (Chiralcel AD-H, 12% $\text{iPrOH}/\text{hexanes}$, 1 mL/min, $t_r(\text{anti, major}) = 30.5$ min, $t_r(\text{anti, minor}) = 12.8$ min, $t_r(\text{syn, major}) = 14.9$ min, $t_r(\text{syn, minor}) = 45.6$ min). Mp 172.0-174.0 °C; $[\alpha]_D^{20} -150$ (*c* 0.13, CHCl_3); $R_f = 0.24$ (20% EtOAc/hexanes); IR (film) 3381, 2982, 1682, 1551, 1521 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 7.50 (d, *J* = 8.4 Hz, 2H), 7.40 (d, *J* = 8.4 Hz, 2H), 7.35 (d, *J* = 8.4 Hz, 2H), 7.28 (d, *J* = 8.8 Hz, 2H), 5.76 (d, *J* = 9.6 Hz, 1H), 5.58 (dd, *J* = 9.6, 9.6 Hz, 1H), 4.78 (d, *J* = 9.6 Hz, 1H), 1.28 (s, 9H); ^{13}C NMR (150 MHz, CDCl_3) ppm 154.2, 136.6, 135.6, 134.9, 130.1, 129.7, 129.3, 129.1, 128.6, 93.2, 80.8, 56.1, 28.0; HRMS (CI): Exact mass calcd for $\text{C}_{19}\text{H}_{21}\text{Cl}_2\text{N}_2\text{O}_4$ [$\text{M}+\text{H}]^+$ 411.0873, found 411.0865.

General Procedure for the Synthesis of Adducts 1b-m. Imine (100 μmol) and $^{6,7}(\text{MeO})_2\text{PBAM}$ (**8d**) (3.1 mg, 5.0 μmol) were dispensed into a vial with a stir bar. Toluene (1.0 mL) was added, and the reaction was stirred at room temperature until homogenous. The reaction mixture was chilled to -78 °C before nitroalkane (110 μmol) was added. The reaction mixture was stirred for 18-26 h. The chilled mixture was diluted with CH_2Cl_2 and quickly filtered through a pad of silica. The silica pad was flushed with EtOAc. The filtrate was concentrated and purified by column chromatography.




tert-Butyl (1*R*,2*S*)-1-(4-chlorophenyl)-2-nitro-2-phenylethylcarbamate (1b). Column chromatography (7-20% ethyl acetate in hexanes) afforded a white solid (35.0 mg, 93%) that was found to be 90% ee and 19:1 dr


Johnston et al.

Supporting Information


by chiral HPLC; (Chiralcel IA, 5% *i*PrOH/hexanes, 1 mL/min, 230 nm, *t_r*(*anti*, major) = 20.4 min, *t_r*(*anti*, minor) = 27.7 min, *t_r*(*syn*, major) = 24.3 min, *t_r*(*syn*, minor) = 46.1 min); mp 177.5–178.5 °C; $[\alpha]_D^{20}$ -28.2 (*c* 0.11, CHCl₃); *R_f* = 0.29 (20% EtOAc/hexanes); IR (film) 3386, 2984, 2924, 1683, 1549, 1520 cm⁻¹; ¹H NMR (600 MHz, CDCl₃) δ 7.54 (d, *J* = 6.6 Hz, 2H), 7.42 (m, 1H), 7.42 (d, *J* = 6.6 Hz, 2H), 7.34 (d, *J* = 9.0 Hz, 2H), 7.29 (d, *J* = 8.4 Hz, 2H), 5.76 (br s, 1H), 5.62 (br s, 1H), 4.84 (br s, 1H), 1.26 (s, 9H); ¹³C NMR (150 MHz, CDCl₃) ppm 154.2, 130.4, 129.2, 128.9, 128.6, 128.6, 94.0, 80.6, 56.1, 28.2. HRMS (ESI): Exact mass calcd for C₁₉H₂₁ClN₂NaO₄ [M+Na]⁺ 399.1088, found 399.1070.



tert-Butyl (1*R*,2*S*)-1-(4-(allyloxy)phenyl)-2-nitro-2-phenylethylcarbamate (1c). Product was made according to the general procedure with the exception that 120 μmol of imine and 100 μmol of nitroalkane were used. Column chromatography (7–25% ethyl acetate in hexanes) afforded a white solid (28.0 mg, 79%) that was found to be 87% ee and 131:1 dr by chiral HPLC; (Chiralcel IA, 12% EtOH/hexanes, 0.5 mL/min, *t_r*(*anti*, major) 14.9 min, *t_r*(*anti*, minor) = 13.1 min, *t_r*(*syn*, major) = 13.8 min, *t_r*(*syn*, minor) = 22.3 min); Mp 174.5–176.0 °C; $[\alpha]_D^{20}$ -42 (*c* 0.16, CHCl₃); *R_f* = 0.21 (20% EtOAc/hexanes); IR (film) 3394, 2981, 2930, 1683, 1549, 1514 cm⁻¹; ¹H NMR (600 MHz, CDCl₃) δ 7.57 (d, *J* = 7.8 Hz, 2H), 7.45–7.37 (m, 3H), 7.26 (d, *J* = 8.4 Hz, 2H), 6.89 (d, *J* = 8.4 Hz, 2H), 6.04 (dd, *J* = 16.8, 10.2, 4.8, 4.8 Hz, 1H), 5.74 (br s, 1H), 5.61 (br s, 1H), 5.41 (dd, *J* = 17.4, 1.2 Hz, 1H), 5.29 (dd, *J* = 10.2, 1.2 Hz, 1H), 4.80 (d, *J* = 7.8 Hz, 1H), 4.52 (d, *J* = 4.8 Hz, 2H) 1.25 (s, 9H); ¹³C NMR (150 MHz, CDCl₃) ppm 158.8, 154.2, 133.0, 131.6, 130.1, 129.7, 128.8 (2C), 128.4, 117.8, 115.1, 94.4, 80.3, 68.8, 56.1, 28.0; HRMS (ESI): Exact mass calcd for C₂₂H₂₆N₂NaO₅ [M+Na]⁺ 421.1739, found 421.1730.



tert-Butyl (1*R*,2*S*)-1-(4-methoxyphenyl)-2-nitro-2-phenylethylcarbamate (1d). Product was made according to the general procedure with the exception that reaction warmed to -20 °C and stirred for 1h before filtration. Column chromatography (7–20% ethyl acetate in hexanes) afforded a white solid (31.0 mg, 83%) that was found to be 85% ee and 81:1 dr by chiral HPLC; (Chiralcel IA, 12% *i*PrOH/hexanes, 0.5 mL/min, *t_r*(*anti*, major) 21.3 min, *t_r*(*anti*, minor) = 23.6 min, *t_r*(*syn*, major) = 19.8 min, *t_r*(*syn*, minor) = 37.0 min); Mp 161.0–162.5 °C; $[\alpha]_D^{20}$ -43 (*c* 0.14, CHCl₃); *R_f* = 0.18 (20% EtOAc/hexanes); IR (film) 3390, 2980, 1683, 1548, 1515 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.60–7.53 (m, 2H), 7.44–7.37 (m, 3H), 7.27 (d, *J* = 8.8 Hz, 2H), 6.88 (d, *J* = 8.8 Hz, 2H), 5.75 (d, *J* = 10.0 Hz, 1H), 5.61 (dd, *J* = 9.2, 9.2 Hz, 1H), 4.80 (d, *J* = 8.8 Hz, 1H), 3.80 (s, 3H), 1.25 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) ppm 159.7, 154.2, 131.6, 130.1, 129.5, 128.8 (2C), 128.4, 114.3, 94.4, 80.3, 56.2, 55.3, 28.0; HRMS (ESI): Exact mass calcd for C₂₀H₂₄N₂NaO₄ [M+Na]⁺ 395.1583, found 395.1567.




tert-Butyl (1*R*,2*S*)-2-nitro-2-phenyl-1-p-tolylethylcarbamate (1e). Product was made according to the general procedure with the exception that 120 μmol of imine and 100 μmol of nitroalkane were used. Column chromatography (7–20% ethyl acetate in hexanes) afforded a white solid (33.0 mg, 93%) that was found to be 91% ee and 38:1 dr by chiral HPLC; (Chiralcel IA, 12% *i*PrOH/hexanes, 0.7 mL/min, *t_r*(*anti*, major) 12.1 min, *t_r*(*anti*, minor) = 13.1 min, *t_r*(*syn*, major) = 11.2 min, *t_r*(*syn*, minor) = 20.7 min); Mp 181.0–183.0 °C; $[\alpha]_D^{20}$ -46


Johnston *et al.*

Supporting Information


(*c* 0.11, CHCl₃); R_f = 0.36 (20% EtOAc/hexanes); IR (film) 3393, 2979, 1685, 1549, 1517 cm⁻¹; ¹H NMR (600 MHz, CDCl₃) δ 7.58 (d, *J* = 7.2 Hz, 2H), 7.45-7.37 (m, 3H), 7.24 (d, *J* = 8.4 Hz, 2H), 7.17 (d, *J* = 7.8 Hz, 2H), 5.75 (br s, 1H), 5.64 (br s, 1H), 4.78 (d, *J* = 9.0 Hz, 1H), 2.34 (s, 3H), 1.24 (s, 9H); ¹³C NMR (150 MHz, CDCl₃) ppm 154.2, 138.6, 134.5, 131.6, 130.1, 129.7, 128.78, 128.76, 127.0, 94.4, 80.2, 56.3, 28.0, 21.1; HRMS (ESI): Exact mass calcd for C₂₀H₂₄N₂NaO₄ [M+Na]⁺ 379.1634, found 379.1626.



tert-Butyl (1*R*,2*S*)-1-(4-fluorophenyl)-2-nitro-2-phenylethylcarbamate (1f). Product was made according to the general procedure with the exception that 120 μmol of imine and 100 μmol of nitroalkane were used. Column chromatography (7-25% ethyl acetate in hexanes) afforded a white solid (35.0 mg, 97%) that was found to be 87% ee and 15:1 dr by chiral HPLC; (Chiralcel IA, 5% EtOH/hexanes, 0.5 mL/min, t_r(*anti*, major) 19.1 min, t_r(*anti*, minor) = 20.5 min, t_r(*syn*, major) = 22.8 min, t_r(*syn*, minor) = 39.9 min); Mp 178.5-180.0 °C; [α]_D²⁰ -18 (*c* 0.15, CHCl₃); R_f = 0.34 (20% EtOAc/hexanes); IR (film) 3391, 2986, 2925, 1683 cm⁻¹; ¹H NMR (600 MHz, CDCl₃) δ 7.56 (dd, *J* = 7.2, 1.2 Hz, 2H), 7.46-7.39 (m, 3H), 7.34 (dd, *J* = 8.4, 4.8 Hz, 2H), 7.05 (dd, *J* = 8.4, 8.4 Hz, 2H), 5.75 (br s, 1H), 5.64 (br s, 1H), 4.81 (d, *J* = 9.0 Hz, 1H), 1.26 (s, 9H); ¹³C NMR (150 MHz, CDCl₃) ppm 162.7 (d, ¹J_{CF} = 246 Hz), 154.2, 133.4, 131.3, 130.3, 129.0 (d, ³J_{CF} = 9.0 Hz), 128.9, 128.7, 116.0 (d, ²J_{CF} = 23 Hz), 94.2, 80.6, 56.2, 28.0; ¹⁹F NMR (376 MHz, CDCl₃) ppm -112.7; HRMS (ESI): Exact mass calcd for C₁₉H₂₁FN₂NaO₄ [M+Na]⁺ 383.1383, found 383.1392.



tert-Butyl (1*R*,2*S*)-2-nitro-2-phenyl-1-(4-(trifluoromethyl)phenyl)ethylcarbamate (1g). Product was made according to the general procedure with the exception that 120 μmol of imine and 100 μmol of nitroalkane were used. Column chromatography (7-20% ethyl acetate in hexanes) afforded a white solid (40.8 mg, 99%) that was found to be 84% ee and 14:1 dr by chiral HPLC; (Chiralcel IA, 8% ¹PrOH/hexanes, 1 mL/min, t_r(*anti*, major) 9.2 min, t_r(*anti*, minor) = 13.9 min, t_r(*syn*, major) = 12.6 min, t_r(*syn*, minor) = 20.0 min); Mp 193.5-194.5 °C; [α]_D²⁰ -21 (*c* 0.14, CHCl₃); R_f = 0.33 (20% EtOAc/hexanes); IR (film) 3390, 2985, 1683, 1548, 1521 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.63 (d, *J* = 8.0 Hz, 2H), 7.58-7.53 (m, 2H), 7.49 (d, *J* = 8.4 Hz, 2H), 7.43-7.40 (m, 3H), 5.80 (br s, 1H), 5.71 (br s, 1H), 4.89 (br s, 1H), 1.26 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) ppm 154.2, 141.5, 131.0, 130.9 (q, ²J_{CF} = 32 Hz), 130.5, 129.0, 128.6, 127.7, 126.0 (q, ³J_{CF} = 4.0 Hz), 123.8 (q, ¹J_{CF} = 271 Hz), 93.7, 80.8, 56.3, 28.0; ¹⁹F NMR (282 MHz, CDCl₃) ppm -61.1; HRMS (ESI): Exact mass calcd for C₂₀H₂₁F₃N₂NaO₄ [M+Na]⁺ 433.1351, found 433.1364.




tert-Butyl (1*R*,2*S*)-1-(biphenyl-4-yl)-2-nitro-2-phenylethylcarbamate (1h). Product was made according to the general procedure with the exception that 120 μmol of imine and 100 μmol of nitroalkane were used. Column chromatography (7-20% ethyl acetate in hexanes) afforded a white solid (41.5 mg, 99%) that was found to be 93% ee and 44:1 dr by chiral HPLC; (Chiralcel AD-H, 10% ¹PrOH/hexanes, 1 mL/min, t_r(*anti*, major) 32.6 min, t_r(*anti*, minor) = 23.9 min, t_r(*syn*, major) = 26.1 min, t_r(*syn*, minor) = 28.7 min); Mp 194.0-196.0 °C; [α]_D²⁰ -56 (*c* 0.15, CHCl₃); R_f = 0.29 (20% EtOAc/hexanes); IR (film) 3398, 2978, 2922, 1686, 1548, 1520 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.63-7.55 (m, 6H), 7.47-7.40 (m, 7H), 7.39-7.33 (m, 1H), 5.82 (br s,


Johnston et al.

Supporting Information


1H), 5.73 (br s, 1H), 4.90 (br s, 1H), 1.27 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) ppm 154.2, 141.6, 140.3, 136.4, 131.5, 130.2, 128.83, 128.80, 128.76, 127.7, 127.59, 127.56, 127.1, 94.2, 80.4, 56.5, 28.0; HRMS (ESI): Exact mass calcd for C₂₅H₂₆N₂NaO₄ [M+Na]⁺ 441.1790, found 471.1776.




tert-Butyl (1*R*,2*S*)-1-(naphthalen-2-yl)-2-nitro-2-phenylethylcarbamate (1i). Product was made according to the general procedure with the exception that 120 µmol of imine and 100 µmol of nitroalkane were used. Column chromatography (7-20% ethyl acetate in hexanes) afforded a white solid (38.9 mg, 99%) that was found to be 91% ee and 25:1 dr by chiral HPLC; (Chiralcel IA, 12% *i*PrOH/hexanes, 1 mL/min, *t*_r(*anti*, major) 10.6 min, *t*_r(*anti*, minor) = 13.2 min, *t*_r(*syn*, major) = 9.2 min, *t*_r(*syn*, minor) = 17.5 min); Mp 183.0-184.5 °C; [α]_D²⁰ -39 (*c* 0.11, CHCl₃); R_f = 0.29 (20% EtOAc/hexanes); IR (film) 3403, 2977, 1688, 1547, 1519 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.89-7.80 (m, 4H), 7.65-7.58 (m, 2H), 7.54-7.48 (m, 2H), 7.48-7.40 (m, 4H), 5.97-5.80 (m, 2H), 4.90 (d, *J* = 8.4 Hz, 1H), 1.25 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) ppm 154.2, 134.8, 133.23, 133.16, 131.5, 130.2, 129.1, 128.9, 128.8, 128.1, 127.7, 126.7, 126.6 (2C), 124.4, 94.2, 80.3, 56.7, 28.0; HRMS (ESI): Exact mass calcd for C₂₃H₂₄N₂NaO₄ [M+Na]⁺ 415.1634, found 415.1635.




tert-Butyl (1*R*,2*S*)-2-(3-bromophenyl)-1-(4-chlorophenyl)-2-nitroethylcarbamate (1j). Column chromatography (7-25% ethyl acetate in hexanes) afforded a white solid (41.5 mg, 91%) that was found to be 89% ee and 13:1 dr by chiral HPLC; (Chiralcel AD-H, 15% *i*PrOH/hexanes, 1 mL/min, *t*_r(*anti*, major) 29.7 min, *t*_r(*anti*, minor) = 14.6 min, *t*_r(*syn*, major) = 13.4 min, *t*_r(*syn*, minor) = 17.2 min); Mp 178.0-179.0 °C; [α]_D²⁰ -39 (*c* 0.15, CHCl₃); R_f = 0.40 (20% EtOAc/hexanes); IR (film) 3388, 2982, 1681, 1549, 1519 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.71 (br s, 1H), 7.58 (ddd, *J* = 8.0, 1.6, 0.8 Hz, 1H), 7.52 (br d, *J* = 8.0 Hz, 1H), 7.35 (d, *J* = 8.8 Hz, 2H), 7.29 (dd, *J* = 7.6, 7.6 Hz, 1H), 7.29 (d, *J* = 8.8 Hz, 2H), 5.75 (br s, 1H), 5.56 (br m, 1H), 4.87 (br s, 1H), 1.29 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) ppm 154.2, 135.6, 134.9, 133.5, 133.3, 131.8, 130.4, 129.3, 128.6, 127.2, 122.8, 93.1, 80.8, 56.3, 28.0; HRMS (ESI): Exact mass calcd for C₁₉H₂₀BrClN₂NaO₄ [M+Na]⁺ 477.0193, found 477.0197.




tert-Butyl (1*R*,2*S*)-1-(4-chlorophenyl)-2-(naphthalen-2-yl)-2-nitroethylcarbamate (1k). Column chromatography (7-25% ethyl acetate in hexanes) afforded a white solid (42.1 mg, 99%) that was found to be 80% ee and 10:1 dr by chiral HPLC; (Chiralcel AD-H, 15% *i*PrOH/hexanes, 1 mL/min, *t*_r(*anti*, major) 53.9 min, *t*_r(*anti*, minor) = 18.0 min, *t*_r(*syn*, major) = 16.7 min, *t*_r(*syn*, minor) = 26.3 min); Mp 185.5-187.0 °C; [α]_D²⁰ -27 (*c* 0.15, CHCl₃); R_f = 0.32 (20% EtOAc/hexanes); IR (film) 3388, 2980, 1683, 1550, 1520 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 8.01 (br s, 1H), 7.92-7.85 (m, 3H), 7.65 (dd, *J* = 8.8, 2.0 Hz, 1H), 7.59-7.52 (m, 2H), 7.38-7.32 (m, 4H), 5.95 (br d, *J* = 8.8 Hz, 1H), 5.72 (br dd, *J* = 9.2, 9.2 Hz, 1H), 4.86 (d, *J* = 8.8 Hz, 1H), 1.18 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) ppm 154.2, 136.1, 134.7, 134.0, 132.8, 129.3, 129.2, 129.0, 128.7, 128.6, 128.3, 127.7, 127.4, 126.9, 124.6, 94.2, 80.7, 56.0, 28.0; HRMS (ESI): Exact mass calcd for C₂₃H₂₃ClN₂NaO₄ [M+Na]⁺ 449.1244, found 449.1256.



tert-Butyl (1R,2S)-1-(4-chlorophenyl)-2-(4-methoxyphenyl)-2-nitroethylcarbamate (1l). Product was made according to the general procedure with the exception that reaction warmed to -20 °C and stirred for 1h before filtration. Column chromatography (7-25% ethyl acetate in hexanes) afforded a white solid (36.5 mg, 90%) that was found to be 86% ee and 17:1 dr by chiral HPLC; (Chiralcel AD-H, 15% iPrOH/hexanes, 1 mL/min, t_r (anti, major) 27.6 min, t_r (anti, minor) = 14.3 min, t_r (syn, major) = 16.7 min, t_r (syn, minor) = 37.9 min); Mp 165.0-166.0 °C; $[\alpha]_D^{20}$ -9.1 (c 0.11, CHCl₃); R_f = 0.27 (20% EtOAc/hexanes); IR (film) 3385, 2981, 1683, 1552, 1514 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.47 (d, J = 8.4 Hz, 2H), 7.33 (d, J = 8.0 Hz, 2H), 7.28 (d, J = 8.4 Hz, 2H), 6.92 (d, J = 8.4 Hz, 2H), 5.68 (br s, 1H), 5.58 (br s, 1H), 4.85 (br s, 1H), 3.82 (s, 3H), 1.26 (s, 9H); ¹³C NMR (150 MHz, CDCl₃) ppm 161.1, 154.3, 136.2, 134.6, 130.1, 129.1, 128.6, 123.2, 114.3, 93.6, 80.6, 56.1, 55.4, 28.1.



tert-Butyl (1R,2S)-1-(4-chlorophenyl)-2-nitro-2-(4-nitrophenyl)ethylcarbamate (1m). Column chromatography (15-30% ethyl acetate in hexanes) afforded a white solid (41.5 mg, 99%) that was found to be 76% ee and 2:1 dr by chiral HPLC; (Chiralcel IA, 10% EtOH/hexanes, 1 mL/min, t_r (d₁, major) 9.8 min, t_r (d₁, minor) = 12.6 min, t_r (d₂, major) = 21.5 min, t_r (d₂, minor) = 52.8 min); Mp 165.5-166.0 °C; R_f = 0.07 (10% EtOAc/hexanes); IR (film) 3405, 2981, 2926, 1681, 1551, 1522 cm⁻¹; ¹H NMR (400 MHz, DMSO-d₆) d₁ δ 8.35 (d, J = 8.8 Hz, 2H), 7.97 (d, J = 8.8 Hz, 2H), 7.55 (d, J = 8.4 Hz, 2H), 7.48 (d, J = 8.4 Hz, 2H), 6.16 (d, J = 11.2 Hz, 1H), 5.57 (dd, J = 10.8, 10.8 Hz, 1H), 1.14 (s, 9H); d₂ δ 8.13 (d, J = 8.8 Hz, 2H), 8.13-8.07 (1H), 7.82 (d, J = 8.8 Hz, 2H), 7.34 (d, J = 8.4 Hz, 2H), 7.25 (d, J = 8.4 Hz, 2H), 6.20 (d, J = 11.2 Hz, 1H), 5.69 (dd, J = 10.4, 10.4 Hz, 1H), 1.34 (s, 9H); ¹³C NMR (100 MHz, DMSO-d₆) ppm 154.5, 154.2, 148.5, 148.3, 138.3, 137.9, 136.9, 136.1, 133.2, 132.6, 130.3, 130.2, 129.8, 129.6, 128.8, 128.5, 123.9, 123.7, 92.2, 91.9, 78.9 (2C), 56.3, 55.6, 28.0, 27.7.



(-)-Nutlin-3 (2).⁵ Tf₂O (28.1 μ L, 166.8 μ mol) was added to a stirred solution of Ph₃PO (92.8 mg, 333.6 μ mol) in CH₂Cl₂ (500 μ L) at 0 °C. The mixture was stirred for 10 min before urea (50.0 mg, 83.4 μ mol) was added as a solution in CH₂Cl₂ (600 μ L), and the reaction was stirred for 1 h at 0 °C. The reaction mixture was allowed to warm to room temperature before addition of aq. NaHCO₃. The organic layer was separated, the aqueous layer was extracted with CH₂Cl₂, and the combined organic layers were then dried over MgSO₄, filtered, and concentrated. Column chromatography (0-4% methanol in dichloromethane) of the residue provided the compound as a white solid (42.5 mg, 88%). Mp 127.0-129.0 °C; $[\alpha]_D^{20}$ -150 (c 0.13, CHCl₃); R_f = 0.24 (5%

⁵ Adapted from Pemberton, N.; Pinkner, J. S.; Edvinsson, S.; Hultgren, S. J.; Almqvist, F. *Tetrahedron* **2008**, 64, 9368-9376.


Johnston *et al.*

Supporting Information


MeOH/CH₂Cl₂); IR (film) 3229, 2980, 2935, 2247, 1678, 1608 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.59 (d, *J* = 8.8 Hz, 1H), 7.08 (d, *J* = 8.4 Hz, 2H), 7.02 (d, *J* = 8.0 Hz, 2H), 6.92 (d, *J* = 8.4 Hz, 2H), 6.86 (d, *J* = 8.4 Hz, 2H), 6.66 (s, 1H), 6.54 (dd, *J* = 8.4, 1.6 Hz, 1H), 6.47 (br s, 1H), 5.55 (d, *J* = 9.6 Hz, 1H), 5.47 (d, *J* = 9.6 Hz, 1H), 4.60 (qq, *J* = 6.0, 6.0 Hz, 1H), 3.83 (s, 3H), 3.75 (d, *J* = 18.0 Hz, 1H), 3.62 (d, *J* = 18.0 Hz, 1H), 3.40-3.31 (m, 1H), 3.23-3.13 (m, 1H), 2.97 (br s, 2H), 1.37 (d, *J* = 6.0 Hz, 3H), 1.32 (d, *J* = 6.0 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) ppm 166.9, 163.0, 160.2, 157.0, 154.7, 136.0, 135.0, 133.1, 132.8, 132.1, 129.2, 128.4, 128.1, 127.9, 113.4, 104.6, 100.1, 71.7, 70.9, 69.1, 55.5, 49.4, 41.8, 40.3, 20.03, 20.01; HRMS (CI): Exact mass calcd for C₃₀H₃₁Cl₂N₄O₄ [M+H]⁺ 581.1717, found 581.1705.

This enantiomer corresponded to “enantiomer-a” using the HPLC conditions as described previously.⁶ The compound was found to be 99% ee; (Chiralcel OD, 30% iPrOH/hexanes, 1 mL/min, *t*_r(major) = 8.6 min, *t*_r(minor) = *not observed*). Additionally, the (+)-enantiomer was prepared using an identical procedure with (*S,S*)-H,⁴PyrrolidineQuin-BAM to form compound **7** (84% ee), which was converted to (+)-Nutlin-3. This compound correlated with “enantiomer-b”. and was found to be 85% ee; (Chiralcel OD, 30% iPrOH/hexanes, 1 mL/min, *t*_r(major) = 10.5 min, *t*_r(minor) = 8.6 min).

Figure 1. Nutlin-3 HMBC Correlations (600 MHz)




Further evidence supporting the structural assignment includes an HMBC (Figure 1), which clearly showed the anticipated couplings for Nutlin-3. C26 (155 ppm) Showed correlations to H27/H27' and H30/H30' and to H1 (but not H8). C15 (160 ppm) Showed correlations to both of the imidazoline methines (H1 and H8) and also to the H25. See SI-2 for HMBC spectrum.




1-Chloro-4-(nitromethyl)benzene (4). 4-Chlorobenzyl bromide (3.000 g, 14.60 mmol) and phloroglucinol (1.841 g, 14.60 mmol) were dissolved in CH₃CN (32.3 mL) in a round bottom flask at room temperature. The reaction mixture was then chilled to 0 °C before IRA900-ONO (12.4 g, 2.4 equiv.) resin was added. The suspension was then stirred at 0 °C for 70 min and filtered. The resin was rinsed thoroughly with diethyl ether. The filtrate and rinsate were combined and concentrated. Column chromatography of the residue (0-3% ethyl acetate in hexanes) afforded a crystalline solid (1.1642 g, 46%). Mp 28.0-29.0 °C; R_f = 0.45 (20% EtOAc/hexanes); IR (film) 3095, 3036, 2916, 1555 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.45-7.35 (m, 4H), 5.41 (s, 2H); ¹³C NMR (100 MHz, CDCl₃) ppm 136.3, 131.4, 129.4, 128.0, 79.1; HRMS (CI): Exact mass calcd for C₇H₇ClNO₂ [M+H]⁺ 172.0160, found 172.0157.

⁶ Wang, Z.; Jonca, M.; Lambros, T.; Ferguson, S.; Goodnow, R. *J. Pharm. Biomed. Anal.* **2007**, 45, 720-729.




H,⁶Me-BAM (7). $\text{Pd}(\text{dba})_2$ (10.1 mg, 17.5 μmol), *rac*-BINAP (21.8 mg, 35.0 μmol), and sodium *tert*-butoxide (286.4 mg, 2.98 mmol) were loaded into a round bottom flask in a glove box. Toluene (10 mL, 0.10M) was added to the mixture, followed by (*R,R*)-diaminocyclohexane (100.0 mg, 876.0 μmol). 2-Bromo-6-methylpyridine (301.5 mg, 1.75 mmol) was added as a solution in toluene. The reaction was allowed to stir at 80°C and monitored by TLC. The reaction was then cooled to room temperature, concentrated, and purified by flash column chromatography on silica gel (5% triethylamine, 10% ethyl acetate in hexanes) affording a white solid (200 mg, 77%). $[\alpha]_D^{20} +110$ (*c* 0.10, CHCl_3); mp 126–128 $^\circ\text{C}$; $R_f = 0.17$ (5% Et_3N , 10% EtOAc /hexanes); IR (neat) 3256, 3051, 2927, 2855, 1559 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 7.19 (dd, $J = 8.0, 8.0$ Hz, 2H), 6.35 (d, $J = 7.2$ Hz, 2H), 6.11 (d, $J = 8.4$ Hz, 2H), 5.16 (br s, 2H), 3.73–3.64 (m, 2H), 2.37 (s, 6H), 2.27–2.18 (m, 2H), 1.78–1.65 (m, 2H), 1.50–1.28 (m, 4H); ^{13}C NMR (100 MHz, CDCl_3) ppm 158.2, 156.5, 137.3, 111.3, 104.2, 55.0, 32.1, 24.4, 24.3; HRMS (EI) Exact mass calcd for $\text{C}_{18}\text{H}_{24}\text{N}_4$ [M]⁺ 296.2001, found 296.1994.


H,⁴PyrrolidineQuin-BAM·HOTf (8a·HOTf). To a flame-dried vial with stir bar was added H,⁴PyrrolidineQuin-BAM (8a) (286.3 mg, 565.1 μmol) and dichloromethane (2 mL). Trifluoromethanesulfonic acid (50.0 μL , 565 μmol) was added dropwise to the stirring solution at room temperature. The reaction mixture was allowed to stir an additional 10 minutes before concentration to a light brown solid that was used without further purification. *Other catalyst acid salts were made in a similar fashion.*




H,⁴Pyrrolidine⁶MeOQuin-BAM (8b). A 2–5 mL microwave vial was charged with H,⁴Cl⁶OMeQuin-BAM (200 mg, 402 μmol), pyrrolidine (660 μL , 8.041 mmol), and trifluoromethylbenzene (2 mL). This suspension was heated at 220°C and stirred in the microwave for 20 min. The reaction was then concentrated and purified by column chromatography (5–10% methanol in dichloromethane) to provide a light brown solid. This material was dissolved in dichloromethane and then washed with 3 M aq NaOH. The combined organic layers were dried over MgSO_4 and concentrated to afford a light brown powder (174.4 mg, 77%); $[\alpha]_D^{20} +350$ (*c* 0.14, CHCl_3); $R_f = 0.29$ (10% $\text{MeOH}/\text{CH}_2\text{Cl}_2$); IR (film) 3261, 2930, 2856, 1595, 1531 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 7.61 (d, $J = 9.2$ Hz, 2H), 7.27 (d, $J = 2.8$ Hz, 2H), 7.11 (dd, $J = 8.8, 2.8$ Hz, 2H), 5.57 (br s, 2H), 5.35 (s, 2H), 4.03 (br s, 2H), 3.82 (s, 6H), 3.32–3.20 (m, 4H), 3.15–3.05 (m, 4H), 2.32–2.25 (m, 2H), 1.90–1.75 (m, 10H), 1.50–1.30 (m, 4H); ^{13}C NMR (100 MHz, CDCl_3) ppm 157.3, 153.0, 152.8, 144.8, 127.5, 118.9, 118.4, 106.0, 94.0, 56.4, 55.6, 51.4, 33.4, 25.4, 25.1; HRMS (ESI): Exact mass calcd for $\text{C}_{34}\text{H}_{43}\text{N}_6\text{O}_2$ [M+H]⁺ 567.3448, found 567.3442.




H,⁴Pyrrolidine⁷MeOQuin-BAM (8c). A 2-5 mL microwave vial was charged with H,⁴Cl⁷MeOQuin-BAM (200 mg, 402 µmol), pyrrolidine (660 µL, 8.041 mmol), and trifluoromethylbenzene (2 mL). This suspension was heated at 220 °C and stirred in the microwave for 20 min. The reaction was then concentrated and purified by column chromatography (5-10% methanol in dichloromethane) to provide a light brown solid. This material was dissolved in dichloromethane and then washed with 3 M aq NaOH. The combined organic layers were dried over MgSO₄ and concentrated to afford a light brown powder (123.5 mg, 54%); [α]_D²⁰ +480 (c 0.13, CHCl₃); R_f = 0.39 (10% MeOH/CH₂Cl₂); IR (film) 3253, 2930, 2855, 1616, 1589, 1526 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 7.76 (d, J = 9.0 Hz, 2H), 7.09 (s, 2H), 6.65 (dd, J = 9.5, 2.5 Hz, 2H), 5.77 (br s, 2H), 5.23 (s, 2H), 4.04 (br s, 2H), 3.88 (s, 6H), 3.35-3.25 (m, 4H), 3.20-3.10 (m, 4H), 2.33-2.25 (m, 2H), 1.90-1.78 (m, 10H), 1.55-1.35 (m, 4H); ¹³C NMR (125 MHz, CDCl₃) ppm 159.9, 158.6, 153.2, 151.5, 125.9, 112.7, 110.4, 105.8, 90.7, 56.3, 55.2, 51.5, 33.3, 25.6, 25.0; HRMS (ESI): Exact mass calcd for C₃₄H₄₃N₆O₂ [M+H]⁺ 567.3447, found 567.3467.




H,⁴Pyrrolidine^{6,7}(MeO)₂Quin-BAM (8d). A 2-5 mL microwave vial was charged with ⁴Cl^{6,7}(MeO)₂Quin-BAM (1.000 g, 1.794 mmol) and pyrrolidine (2.9 mL, 36 mmol). This suspension was heated at 180 °C and stirred in the microwave for 40 min. The reaction was then concentrated and purified by column chromatography (2-5-10% methanol in dichloromethane with 1% AcOH) to provide a light brown solid. This material was dissolved in dichloromethane and then washed with 3 M aq NaOH. The combined organic layers were dried over MgSO₄ and concentrated. The material was then triturated with hexanes to afford a light brown viscous foam (351.1 mg, 31%); [α]_D²⁰ +340 (c 0.11, CHCl₃); R_f = 0.22 (10% MeOH/1% AcOH/CH₂Cl₂); IR (film) 3391, 2931, 2855, 1593 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.24 (s, 2H), 7.10 (s, 2H), 5.51 (br s, 2H), 5.37 (s, 2H), 3.99 (br s, 2H), 3.99 (s, 6H), 3.89 (s, 6H), 3.37-3.26 (m, 4H), 3.23-3.13 (m, 4H), 2.35-2.25 (m, 2H), 1.91-1.79 (m, 10H), 1.52-1.38 (m, 4H); ¹³C NMR (100 MHz, CDCl₃) ppm 157.6, 152.8, 150.7, 146.0, 143.5, 111.7, 106.5, 105.2, 91.9, 56.3, 55.8, 55.5, 51.2, 33.3, 25.3, 25.0; HRMS (CI): Exact mass calcd for C₃₆H₄₇N₆O₄ [M+H]⁺ 627.3653, found 627.3658.




1-Bromo-3-(nitromethyl)benzene (17). NaNO₂ (414.0 mg, 6.000 mmol), urea (721.2 mg, 12.00 mmol), and phloroglucinol (756.7 mg, 6.000 mmol) were stirred with DMF (9.1 mL) at room temperature until homogenous. The reaction mixture was chilled to -20 °C before the addition of bromide (1.4996 g, 6.000 mmol). The mixture was stirred at -20 °C for 5.5 h before pouring into ice water. The mixture was extracted with ether. The combined organic extracts were washed with water, dried over MgSO₄, filtered, and concentrated. Column chromatography (0-10% EtOAc/hexanes) provided a clear, slightly green oil (379.9 mg, 29%). R_f = 0.23 (10% EtOAc/hexanes); IR (film) 3064, 2914, 1553 cm⁻¹; ¹H NMR (600 MHz, CDCl₃) δ 7.64-7.61 (m, 1H), 7.59 (d, J = 8.4 Hz, 1H), 7.40 (d, J = 7.8 Hz, 1H), 7.32 (dd, J = 7.8, 7.8 Hz), 5.40 (s, 2H); ¹³C NMR (150 MHz, CDCl₃) ppm 133.2, 133.0, 131.4, 130.6, 128.6, 122.9, 79.1; HRMS (CI): Exact mass calcd for C₇H₆BrNO₂ [M]⁺ 214.9576, found 214.9575.




2-(Nitromethyl)naphthalene (18). NaNO₂ (1.035 g, 15.00 mmol), urea (1.202 g, 20.00 mmol), phloroglucinol (1.261 g, 10.00 mmol), and bromide (2.211 g, 10.00 mmol) were reacted according to the aforementioned procedure but with a reaction time of 5 h. Column chromatography (0-3% EtOAc/hexanes) provided a yellow solid (358.4 mg, 19%). Mp 81.5-82.5 °C. R_f = 0.30 (10% EtOAc/hexanes); IR (film) 3060, 2910, 1550 cm⁻¹; ¹H NMR (600 MHz, CDCl₃) δ 7.94-7.85 (m, 4H), 7.59-7.52 (m, 3H), 5.60 (s, 2H); ¹³C NMR (150 MHz, CDCl₃) ppm 133.6, 133.0, 130.0, 129.0, 128.2, 127.8, 127.2, 127.0, 126.8, 126.4, 80.2; HRMS (CI): Exact mass calcd for C₁₁H₉NO₂ [M]⁺ 187.0628, found 187.0634.



2-Isopropoxy-4-methoxybenzoic acid (21).³ Ester (985.0 mg, 3.904 mmol) was boiled with KOH (703.8 mg, 12.54 mmol) in a mixture of ethanol (11.7 mL) and water (2.3 mL) for 4 h. EtOH was then removed by evaporation. The remaining material was diluted with water and treated with 3 M HCl until precipitation occurred. The suspension was then extracted with diethyl ether. The combined organic layers were washed with brine before drying over MgSO₄. The solution was concentrated to a red oil (733.2 mg, 89%) that was pure by ¹H NMR. R_f = 0.33 (50% EtOAc/hexanes); IR (film) 3261, 2981, 1730, 1608 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 10.91 (br s, 1H), 8.12 (d, J = 9.0 Hz, 1H), 6.62 (dd, J = 9.0, 2.5 Hz, 1H), 6.52 (d, J = 2.0 Hz, 1H), 4.81 (heptet, J = 6.5 Hz, 1H), 3.86 (s, 3H), 1.47 (d, J = 6.0 Hz, 6H); ¹³C NMR (100 MHz, CDCl₃) ppm 165.5, 164.9, 157.8, 135.4, 111.4, 106.8, 100.7, 73.9, 55.7, 21.9; HRMS (ESI): Exact mass calcd for C₁₁H₁₄NaO₄ [M+Na]⁺ 233.0790, found 233.0795.



tert-Butyl (1*R*,2*S*)-1,2-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxybenzamido)ethylcarbamate (22). The amine (170.0 mg, 445.8 μmol) and carboxylic acid (93.7 mg, 445.8 μmol) were dissolved in CH₂Cl₂ (2.2 mL) at room temperature. The solution was chilled to 0 °C and EDC (111.1 mg, 579.6 μmol) and DMAP (5.4 mg, 44.6 μmol) were added. The reaction mixture was stirred and allowed to gradually warm to room temperature. After 16 h, the reaction mixture was diluted with water and extracted with CH₂Cl₂. The combined organic layers were washed once with water, dried over MgSO₄, and concentrated. The resulting white solid was washed with CH₂Cl₂ and hexanes, leaving a white solid (224.5 mg, 88%) that was pure by NMR. Mp 239.0-241.0 °C (decomp.); [α]_D²⁰ -29 (c 0.13, CHCl₃); R_f = 0.13 (20% EtOAc/hexanes); IR (film) 3355, 2976, 1680, 1629, 1607, 1529 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 8.39 (d, J = 7.2 Hz, 1H), 8.19 (d, J = 8.8 Hz, 1H), 7.26 (d, J = 8.4 Hz, 2H), 7.21 (d, J = 8.4 Hz, 2H), 7.02 (d, J = 6.8 Hz, 2H), 6.93 (d, J = 8.4 Hz, 2H), 6.59 (dd, J = 8.8, 2.4 Hz, 1H), 6.46 (d, J = 1.6 Hz, 1H), 5.91 (br s, 1H), 5.78 (br s, 1H), 5.07 (br s, 1H), 4.75-4.60 (m, 1H), 3.84 (s, 3H), 1.38 (s, 9H), 1.30-1.21 (m, 6H); ¹³C NMR (100 MHz, CDCl₃) ppm 165.6, 163.6, 157.2, 155.0, 136.9, 136.7, 134.2, 133.6, 133.3, 128.6 (2C), 128.5, 128.3, 114.1, 105.2, 100.2, 79.9, 71.4, 59.5, 56.6, 55.5, 28.3, 22.0, 21.6; HRMS (ESI): Exact mass calcd for C₃₀H₃₄Cl₂N₂NaO₅ [M+Na]⁺ 595.1742, found 595.1743.



2-Oxo-piperazine (23).⁷ The resulting orange oil was purified by column chromatography (10% MeOH in CH₂Cl₂ w/ 1% NH₄OH). A yellow solid (2.8634 g, 71%) was obtained that was sufficiently pure by ¹H NMR. R_f = 0.07 (10% MeOH/CH₂Cl₂ w/ 1% NH₄OH); IR (film) 3400, 1650 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 7.18 (br s, 1H), 3.46 (s, 2H), 3.35-3.28 (m, 2H), 2.98 (t, J = 5.5 Hz, 2H), 1.89 (br s, 1H); ¹³C NMR (125 MHz, CDCl₃) ppm 170.4, 49.6, 42.7, 42.2; HRMS (CI): Exact mass calcd for C₄H₉N₂O [M+H]⁺ 101.0709, found 101.0714.

⁷ Elmaleh, D. R.; Choi, S.-W. Diagnostic and therapeutic piperazine and piperidine compounds and process. U.S. Patent 6,835,371, December 28, 2004.

Catalytic, Enantioselective Synthesis of Stilbene *cis*-Diamines:
A Concise Preparation of (-)-Nutlin 3, a Potent p53-MDM2 Inhibitor

Tyler A. Davis and Jeffrey N. Johnston*

Department of Chemistry & Vanderbilt Institute of Chemical Biology
Vanderbilt University
2301 Vanderbilt Place, Nashville, TN 37235-1822

S-II-X

Figure 1. ^1H NMR (400 MHz, CDCl_3) of S1	3
Figure 2. ^{13}C NMR (150 MHz, CDCl_3) of S1	4
Figure 3. Crystal Structure of S1	5
Figure 4. ^1H NMR (400 MHz, CDCl_3) of S2	6
Figure 5. ^{13}C NMR (100 MHz, CDCl_3) of S2	7
Figure 6. ^1H NMR (400 MHz, CDCl_3) of S3	8
Figure 7. ^{13}C NMR (100 MHz, CDCl_3) of S3	9
Figure 8. ^1H NMR (400 MHz, CDCl_3) of S4	10
Figure 9. ^{13}C NMR (100 MHz, CDCl_3) of S4	11
Figure 10. ^1H NMR (500 MHz, CDCl_3) of S5	12
Figure 11. ^{13}C NMR (125 MHz, CDCl_3) of S5	13
Figure 12. ^1H NMR (600 MHz, CDCl_3 , 325 K) of S6	14
Figure 13. ^{13}C NMR (150 MHz, CDCl_3 , 325 K) of S6	15
Figure 14. ^1H NMR (400 MHz, CDCl_3) of S7	16
Figure 15. ^{13}C NMR (100 MHz, CDCl_3) of S7	17
Figure 16. ^1H NMR (500 MHz, CDCl_3 , 325 K) of S8	18
Figure 17. ^{13}C NMR (100 MHz, CDCl_3 , 325 K) of S8	19
Figure 18. ^1H NMR (400 MHz, CDCl_3 , 330 K) of S9	20
Figure 19. ^{13}C NMR (100 MHz, CDCl_3 , 330 K) of S9	21
Figure 20. ^1H NMR (400 MHz, CDCl_3) of S10	22
Figure 21. ^{13}C NMR (100 MHz, CDCl_3) of S10	23
Figure 22. ^1H NMR (400 MHz, CDCl_3) of 1a	24
Figure 23. ^{13}C NMR (150 MHz, CDCl_3) of 1a	25
Figure 24. ^1H NMR (600 MHz, CDCl_3) of 1b	26
Figure 25. ^{13}C NMR (150 MHz, CDCl_3) of 1b	27
Figure 26. ^1H NMR (600 MHz, CDCl_3) of 1c	28
Figure 27. ^{13}C NMR (150 MHz, CDCl_3) of 1c	29
Figure 28. ^1H NMR (400 MHz, CDCl_3) of 1d	30
Figure 29. ^{13}C NMR (100 MHz, CDCl_3) of 1d	31
Figure 30. ^1H NMR (600 MHz, CDCl_3) of 1e	32
Figure 31. ^{13}C NMR (150 MHz, CDCl_3) of 1e	33
Figure 32. ^1H NMR (600 MHz, CDCl_3) of 1f	34
Figure 33. ^{13}C NMR (150 MHz, CDCl_3) of 1f	35
Figure 34. ^1H NMR (400 MHz, CDCl_3) of 1g	36
Figure 35. ^{13}C NMR (100 MHz, CDCl_3) of 1g	37
Figure 36. ^1H NMR (400 MHz, CDCl_3) of 1h	38
Figure 37. ^{13}C NMR (100 MHz, CDCl_3) of 1h	39
Figure 38. ^1H NMR (400 MHz, CDCl_3) of 1i	40
Figure 39. ^{13}C NMR (100 MHz, CDCl_3) of 1i	41
Figure 40. ^1H NMR (400 MHz, CDCl_3) of 1j	42

Figure 41. ^{13}C NMR (100 MHz, CDCl_3) of 1j	43
Figure 42. ^1H NMR (400 MHz, CDCl_3) of 1k	44
Figure 43. ^{13}C NMR (100 MHz, CDCl_3) of 1k	45
Figure 44. ^1H NMR (400 MHz, CDCl_3) of 1l	46
Figure 45. ^{13}C NMR (100 MHz, CDCl_3) of 1l	47
Figure 46. ^1H NMR (400 MHz, DMSO-d_6) of 1m	48
Figure 47. ^{13}C NMR (100 MHz, DMSO-d_6) of 1m	49
Figure 48. ^1H NMR (400 MHz, CDCl_3) of 2	50
Figure 49. ^{13}C NMR (100 MHz, CDCl_3) of 2	51
Figure 50. HMBC (600 MHz, CDCl_3) of 2	52
Figure 51. HMBC (600 MHz, CDCl_3) of 2	53
Figure 52. ^1H NMR (400 MHz, CDCl_3) of 4	54
Figure 53. ^{13}C NMR (100 MHz, CDCl_3) of 4	55
Figure 54. ^1H NMR (400 MHz, CDCl_3) of 7	56
Figure 55. ^{13}C NMR (100 MHz, CDCl_3) of 7	57
Figure 56. ^1H NMR (400 MHz, CDCl_3) of 8b	58
Figure 57. ^{13}C NMR (100 MHz, CDCl_3) of 8b	59
Figure 58. ^1H NMR (500 MHz, CDCl_3) of 8c	60
Figure 59. ^{13}C NMR (125 MHz, CDCl_3) of 8c	61
Figure 60. ^1H NMR (400 MHz, CDCl_3) of 8d	62
Figure 61. ^{13}C NMR (100 MHz, CDCl_3) of 8d	63
Figure 62. ^1H NMR (600 MHz, CDCl_3) of 17	64
Figure 63. ^{13}C NMR (150 MHz, CDCl_3) of 17	65
Figure 64. ^1H NMR (600 MHz, CDCl_3) of 18	66
Figure 65. ^{13}C NMR (150 MHz, CDCl_3) of 18	67
Figure 66. ^1H NMR (500 MHz, CDCl_3) of 21	68
Figure 67. ^{13}C NMR (100 MHz, CDCl_3) of 21	69
Figure 68. ^1H NMR (400 MHz, CDCl_3) of 22	70
Figure 69. ^{13}C NMR (100 MHz, CDCl_3) of 22	71
Figure 70. ^1H NMR (500 MHz, CDCl_3) of 23	72
Figure 71. ^{13}C NMR (125 MHz, CDCl_3) of 23	73








Figure 2. ^{13}C NMR (150 MHz, CDCl_3) of **S1**





SCHAKAL






Figure 6. ^1H NMR (400 MHz, CDCl_3) of **S3**




Figure 7. ^{13}C NMR (100 MHz, CDCl_3) of **S3**




Figure 8. ^1H NMR (400 MHz, CDCl_3) of **S4**




Figure 9. ^{13}C NMR (100 MHz, CDCl_3) of **S4**




Figure 10. ^1H NMR (500 MHz, CDCl_3) of S5




Figure 11. ^{13}C NMR (125 MHz, CDCl_3) of S5





Figure 12. ^1H NMR (600 MHz, CDCl_3 , 325 K) of **S6**




Figure 13. ^{13}C NMR (150 MHz, CDCl_3 , 325 K) of **S6**




Figure 14. ^1H NMR (400 MHz, CDCl_3) of S7




Figure 15. ^{13}C NMR (100 MHz, CDCl_3) of S7

```

NAME          t_acq2-226
EXPO          8.2
PRONO        1
DATE_        20100223
TIME         10.57
INSTRUM      5 mm PABBI 1H
FROBHD      zppg930
FUPFRG      30768
TD           30768
SOLVENT      CDCl3
NS           512
DS           8
SWH          25252.525 Hz
FIDRES      0.770645 Hz
AQ           0.6489762 sec
RG           153.84
DR           19.800 usec
DE           6.000 usec
TE           298.0 K
DI           1.5000000 sec
D1           0.0300000 sec
D11          1.3999999 sec
DELTA         1
TDO          1

===== CHANNEL f1 =====
NUC1          13C
P1            15.50 usec
PL1           -1.80 dB
SFO1          100.622303 MHz

===== CHANNEL f2 =====
CPPIRG2      Waertz 1H
NUC2          1H
PCDD2         100.00 usec
PL2           -3.50 dB
PL12          17.81 dB
PL13          17.81 dB
SFO2          400.132007 MHz
SI            30768
SF           100.6127739 MHz
WDW          End
SSB           0
LB            1.50 Hz
GB           0
PC           1.40

```






Figure 16. ^1H NMR (500 MHz, CDCl_3 , 325 K) of **S8**






Figure 18. ^1H NMR (400 MHz, CDCl_3 , 330 K) of **S9**




Figure 19. ^{13}C NMR (100 MHz, CDCl_3 , 330 K) of **S9**




Figure 20. ^1H NMR (400 MHz, CDCl_3) of **S10**




Figure 21. ^{13}C NMR (100 MHz, CDCl_3) of **S10**





Figure 22. ^1H NMR (400 MHz, CDCl_3) of **1a**




Figure 23. ^{13}C NMR (150 MHz, CDCl_3) of **1a**




Figure 24. ^1H NMR (600 MHz, CDCl_3) of **1b**




Figure 25. ^{13}C NMR (150 MHz, CDCl_3) of **1b**





Figure 26. ^1H NMR (600 MHz, CDCl_3) of **1c**






Figure 28. ^1H NMR (400 MHz, CDCl_3) of **1d**





Figure 29. ^{13}C NMR (100 MHz, CDCl_3) of **1d**






Figure 31. ^{13}C NMR (150 MHz, CDCl_3) of **1e**






Figure 32. ^1H NMR (600 MHz, CDCl_3) of **1f**





Johnston *et al.*

Figure 34. ^1H NMR (400 MHz, CDCl_3) of **1g**

Supporting Information-II




Figure 35. ^{13}C NMR (100 MHz, CDCl_3) of **1g**




Figure 36. ^1H NMR (400 MHz, CDCl_3) of **1h**




Figure 37. ^{13}C NMR (100 MHz, CDCl_3) of **1h**





Figure 38. ^1H NMR (400 MHz, CDCl_3) of **1i**







Figure 40. ^1H NMR (400 MHz, CDCl_3) of **1j**








Figure 42. ^1H NMR (400 MHz, CDCl_3) of **1k**






Figure 44. ^1H NMR (400 MHz, CDCl_3) of **1l**




Figure 45. ^{13}C NMR (100 MHz, CDCl_3) of **1l**





Figure 46. ^1H NMR (400 MHz, DMSO-d₆) of **1m**






Figure 48. ^1H NMR (400 MHz, CDCl_3) of **2**





Figure 49. ^{13}C NMR (100 MHz, CDCl_3) of 2







Figure 51. HMBC (600 MHz, CDCl₃) of 2



C26 (155 ppm) Showed correlations to H27/H27' and H30/H30' and to H1 (but not H8). C15 (160 ppm) Showed correlations to both of the imidazoline methines (H1 and H8) and also to the H25.




Figure 52. ^1H NMR (400 MHz, CDCl_3) of **4**

1H

Current Data Parameters
NAME tad3-268
EXPNO 11
PROCNO 1

F2 - Acquisition Parameters
Date 20090725
Time 14:32
TDIM 1
PROBOD 5 mm PAB3_110/
PULPROG zg30
TD 32768
SOLVENT CDCl₃
NS 16
DS 0
SWH 5.028333 Hz
FIDRES 0.188946 Hz
AQ 3.1498120 sec
RG 128
DW 96.000 usec
DE 6.00 usec
TE 298.0 K
D1 1.5000000 sec
TDO 1

===== CHANNEL f1 =====

NUC1 1H

P1 8.0 usec

P1 4.10 deg

SP 400.1300007 Hz

SW1 32768

SF 400.1300097 MHz

WDW

SSB 0

LB 0

GB 0

PC 1.00

F2 - Processing parameters

SI 32768

SP 400.1300097 Hz

EM

SSB 0

LB 0

GB 0

PC 1.00





Figure 53. ^{13}C NMR (100 MHz, CDCl_3) of 4




Figure 54. ^1H NMR (400 MHz, CDCl_3) of 7




Figure 55. ^{13}C NMR (100 MHz, CDCl_3) of 7




Figure 56. ^1H NMR (400 MHz, CDCl_3) of **8b**




Figure 57. ^{13}C NMR (100 MHz, CDCl_3) of **8b**




Figure 58. ^1H NMR (500 MHz, CDCl_3) of **8c**




Figure 59. ^{13}C NMR (125 MHz, CDCl_3) of **8c**




Figure 60. ^1H NMR (400 MHz, CDCl_3) of **8d**





Figure 61. ^{13}C NMR (100 MHz, CDCl_3) of **8d**



```

NAME          tad4-045_f25-40
EXNO         3
PROCNO      1
Date_        2001/02/1
Time         13:30
INSTRUM     spect
PROBHD      5 mm PABBO BB-
PULPROG    zap930
TD          32768
SOLVENT     CDCl3
NS           10
DS           101
SWH         26178.070 Hz
AQ          0.78809 sec
TDZ         16384
RG          1.6300 usec
DW          6.00 usec
TE          2.981 K
D1          2.000000 sec
D11         0.0300000 sec
TQO          1

```

```

===== CHANNEL f1 =====
NUCL1       13C
P1          12.00 usec
P11         -1.00 dB
P11W        37.63110342 W
P12W        100.62283634 MHz
SI01

```

```

===== CHANNEL f2 =====
CPDPNG2    waltz16
NUC2         1H
PPD2        80.00 usec
P12         2.00 dB
P112        14.44 dB
P113        14.44 dB
P12W        18.35839538 W
P112W       0.37159937 W
P113W       0.37159937 W
SI02        400.133007 MHz
SF          100.6127982 MHz
SSB         0.00 Hz
LB          1.00 Hz
GB          0
PC          1.40

```




Figure 62. ^1H NMR (600 MHz, CDCl_3) of **17**




Figure 63. ^{13}C NMR (150 MHz, CDCl_3) of **17**




Figure 64. ^1H NMR (600 MHz, CDCl_3) of **18**




Figure 65. ^{13}C NMR (150 MHz, CDCl_3) of **18**




Figure 66. ^1H NMR (500 MHz, CDCl_3) of **21**




Figure 67. ^{13}C NMR (100 MHz, CDCl_3) of **21**




Figure 68. ^1H NMR (400 MHz, CDCl_3) of 22




Figure 69. ^{13}C NMR (100 MHz, CDCl_3) of **22**




Figure 70. ^1H NMR (500 MHz, CDCl_3) of 23




Figure 71. ^{13}C NMR (125 MHz, CDCl_3) of **23**

